Skip to content

Study · Animal study (in vivo) · 2020

5 results

A glycosylated Fc-fused glucagon-like peptide-1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide.

An IB, Byun MS, Yang SI, Choi Y, Woo JW, Jang HC, Sung YC

Diabetes, obesity & metabolism3 Jun 2020Cited by 5 (Europe PMC)

PMID32314505 (opens in a new tab)PMCIDPMC7383507 (opens in a new tab)DOI10.1111/dom.14058 (opens in a new tab)PepBankPUB-32314505
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In animal testing, HbA1c changes with dulaglutide and potency-adjusted GLP-1-gFc did not differ significantly.

    In plain wordsIn animals, HbA1c changes did not differ significantly between dulaglutide and potency-adjusted GLP-1-gFc.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHbA1c change
    Study

    n: not reported in source

    Comparator
    GLP-1-gFc
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.6 mg/kg · 6 weeksAs given in this study.

    Measurements

    HbA1c change
    4.26 not stated
    dulaglutide

    Source sentences

    Summary
    A potency-adjusted dose delayed HbA1c increase comparable with that of dulaglutide (Change for 6 weeks: 2.4 mg/kg GLP-1-gFc, 4.34 ± 0.40 vs. 0.6 mg/kg dulaglutide, 4.26 ± 0.22; n.s.).
    1 context sentence
    Summary · context
    We constructed GLP-1-gFc and determined its binding affinity and potency using in vitro instrumental and cell-based analyses followed by in vivo comparison of the glucose-lowering and gastrointestinal side effects between GLP-1-gFc and dulaglutide.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In animal testing, blueberry bar consumption was lower with dulaglutide than GLP-1-gFc, consistent with more malaise-related responses.

    In plain wordsIn animals, dulaglutide reduced blueberry bar consumption more than GLP-1-gFc, a measure of malaise.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMalaise-related blueberry bar consumption
    Study

    n: not reported in source

    Comparator
    GLP-1-gFc
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.6 mg/kgAs given in this study.

    Source sentences

    Summary
    However, the equivalent efficacy dose and higher dose did not induce malaise-related responses (blueberry bar consumption, g/mouse: 2.4 mg/kg GLP-1-gFc, 0.15% ± 0.03% vs. 0.6 mg/kg dulaglutide, 0.04% ± 0.01%; P < .01)
    1 context sentence
    Summary · context
    We constructed GLP-1-gFc and determined its binding affinity and potency using in vitro instrumental and cell-based analyses followed by in vivo comparison of the glucose-lowering and gastrointestinal side effects between GLP-1-gFc and dulaglutide.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In animal testing, QT interval changes did not differ significantly between dulaglutide and GLP-1-gFc.

    In plain wordsIn animals, heart electrical timing changes did not differ significantly between dulaglutide and GLP-1-gFc.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeQT interval changes
    Study

    n: not reported in source

    Comparator
    GLP-1-gFc
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    0.07 mg/kgAs given in this study.

    Source sentences

    Summary
    or QT interval changes (mean at 14-20 hours, mSc: 0.28 mg/kg GLP-1-gFc, 0.0-8.0 vs. 0.07 mg/kg dulaglutide, 8.0-27.7; n.s.), observed as safety variables in rats and monkeys, compared with those of dulaglutide.
    1 context sentence
    Summary · context
    We constructed GLP-1-gFc and determined its binding affinity and potency using in vitro instrumental and cell-based analyses followed by in vivo comparison of the glucose-lowering and gastrointestinal side effects between GLP-1-gFc and dulaglutide.
  4. 04LabIn vitro (cells)Activity measurement

    In vitro, dulaglutide had greater potency than GLP-1-gFc, which showed 4-fold less potency.

    In plain wordsIn cells, dulaglutide had greater potency than GLP-1-gFc.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseReceptor agonist potency
    Study

    n: not reported in source

    In vitro cell-based assay
    Comparator
    GLP-1-gFc
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GLP-1-gFc showed 10-fold less binding affinity and 4-fold less potency than dulaglutide in in vitro.
    1 context sentence
    Summary · context
    We constructed GLP-1-gFc and determined its binding affinity and potency using in vitro instrumental and cell-based analyses followed by in vivo comparison of the glucose-lowering and gastrointestinal side effects between GLP-1-gFc and dulaglutide.
  5. 05LabIn vitro (cell-free)Activity measurement

    In vitro, dulaglutide had greater receptor binding affinity than GLP-1-gFc, which showed 10-fold less affinity.

    In plain wordsIn lab tests, dulaglutide bound the receptor more strongly than GLP-1-gFc.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseReceptor binding affinity
    Study

    n: not reported in source

    In vitro binding assay
    Comparator
    GLP-1-gFc
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GLP-1-gFc showed 10-fold less binding affinity and 4-fold less potency than dulaglutide in in vitro.
    1 context sentence
    Summary · context
    We constructed GLP-1-gFc and determined its binding affinity and potency using in vitro instrumental and cell-based analyses followed by in vivo comparison of the glucose-lowering and gastrointestinal side effects between GLP-1-gFc and dulaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.